周五， 诺和诺德 盘前拉升，涨幅超5%。公司重磅减肥药Wegovy的高剂量版本获英国药品和保健品监管局（MHRA）批准。
英国批准的7.2mg剂量是目前标准最高剂量（2.4mg）的三倍，临床试验显示其减重效果显著：72周后患者平均减重20.7%，三分之一受试者减重超25%。这一突破被视为诺和诺德在GLP-1领域对抗礼来替尔泊肽的关键反击，有望进一步巩固其在全球减重市场的领导地位。
此外，贝伦贝格银行同日将诺和诺德目标价上调至415丹麦克朗，叠加欧股开盘上涨近3%的联动效应，共同推动了此次股价跃升。市场预期该高剂量版本将加速在全球主要市场的申报，包括中国这一关键战略市场。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
